Smileyscope, an Austin, TX-based company advancing digital therapeutics, raised an undisclosed amount in Seed Prime funding.
The round included investments from Breakthrough Victoria, Ten13, Alice Anderson Fund and MedAngels.
The company intends to use the funds to grow its clinical-stage pipeline, and expand across the health systems in the United States and Australia.
Led by CEO Dr. Evelyn Chan, Rhodes Scholar and Dr. Paul Leong, Smileyscope is a company specializes in virtual and augmented reality (VR/AR) therapeutics focused on managing pain, anxiety, and mental health for patients. It has patented innovations in VR/AR and has a medically-designed virtual reality headset worldwide. The company currently has multiple clinical trials underway and is rapidly expanding its product offerings into additional patient segments.
Smileyscope’s flagship product is designed to reduce pain and anxiety during common pediatric procedures. By using their patented therapy software, known as Procedural Choreography, Smileyscope replaces negative real-world stimuli with positive virtual stimuli, reducing procedural pain and anxiety.
Smileyscope has been adopted in 100% of Australian Children’s Hospitals and is operationally profitable in Australia. It is rapidly expanding across Children’s Hospitals throughout the US, including Children’s Hospital of Orange County, Boston Children’s, Nicklaus Children’s, and numerous other Best Children’s Hospitals ranked in the U.S. News & World Report’s 2022-23.
FinSMEs
04/10/2023